Physician profile
John H Karan
NPI 1720007545
$3,717.87
in general payments reported to CMS, 2019-2025
24 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $167 · 2021: $475 · 2022: $382 · 2023: $756 · 2024: $209 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $709 · Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $709.08 |
| Food and Beverage | $517.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,907.11 | 2019-2023 | Vns Therapy |
| Neurocrine Biosciences, INC. | $320.01 | 2019-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $241.76 | 2021-2022 | |
| Biogen, INC. | $172.03 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $149.22 | 2024-2025 | Crexont, Rytary |
| Teva Pharmaceuticals USA, INC. | $147.93 | 2019-2024 | Austedo Xr |
| Ani Pharmaceuticals, INC. | $105.63 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $92.98 | 2024-2025 | |
| Ucb, INC. | $68.68 | 2021-2022 | |
| Eisai INC. | $67.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $60.51 | 2021 | |
| Acadia Pharmaceuticals INC | $57.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.20 | 2021 | |
| Genentech USA, INC. | $48.27 | 2022-2025 | Ocrevus Zunovo |
| Genzyme Corporation | $42.75 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.83 | 2019 | |
| Sk Life Science, INC. | $26.02 | 2020-2021 | |
| Mdd US Operations, LLC | $24.04 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.42 | 2019 | |
| Scilex Pharmaceuticals INC. | $20.23 | 2024 | |
| Abbott Laboratories | $14.01 | 2021 | |
| Tanabe Pharma America, INC. | $13.55 | 2025 | Radicava |
| Celgene Corporation | $13.53 | 2025 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Karan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.